These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9628841)

  • 61. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.
    Dahari H; Shudo E; Cotler SJ; Layden TJ; Perelson AS
    Antivir Ther; 2009; 14(3):459-64. PubMed ID: 19474480
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.
    Dahari H; Layden-Almer JE; Kallwitz E; Ribeiro RM; Cotler SJ; Layden TJ; Perelson AS
    Gastroenterology; 2009 Apr; 136(4):1402-9. PubMed ID: 19208338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatitis C Viral Kinetics in Special Populations.
    Dahari H; Layden-Almer JE; Perelson AS; Layden TJ
    Curr Hepat Rep; 2008; 7(3):97-105. PubMed ID: 19148305
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modeling complex decay profiles of hepatitis B virus during antiviral therapy.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Hepatology; 2009 Jan; 49(1):32-8. PubMed ID: 19065674
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal timing and duration of induction therapy for HIV-1 infection.
    Curlin ME; Iyer S; Mittler JE
    PLoS Comput Biol; 2007 Jul; 3(7):e133. PubMed ID: 17630827
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.
    Dahari H; Lo A; Ribeiro RM; Perelson AS
    J Theor Biol; 2007 Jul; 247(2):371-81. PubMed ID: 17451750
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Viral and latent reservoir persistence in HIV-1-infected patients on therapy.
    Kim H; Perelson AS
    PLoS Comput Biol; 2006 Oct; 2(10):e135. PubMed ID: 17040122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.
    Labbé L; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):519-42. PubMed ID: 16786410
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
    Csajka C; Verotta D
    J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.
    Barrett JS; Labbé L; Pfister M
    Clin Pharmacokinet; 2005; 44(6):591-625. PubMed ID: 15910009
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A parameter sensitivity methodology in the context of HIV delay equation models.
    Banks HT; Bortz DM
    J Math Biol; 2005 Jun; 50(6):607-25. PubMed ID: 15614552
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus.
    Briones C; Domingo E; Molina-París C
    J Mol Biol; 2003 Aug; 331(1):213-29. PubMed ID: 12875847
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.
    Mittler J; Essunger P; Yuen GJ; Clendeninn N; Markowitz M; Perelson AS
    Antimicrob Agents Chemother; 2001 May; 45(5):1438-43. PubMed ID: 11302807
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.
    Ferguson NM; deWolf F; Ghani AC; Fraser C; Donnelly CA; Reiss P; Lange JM; Danner SA; Garnett GP; Goudsmit J; Anderson RM
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15167-72. PubMed ID: 10611356
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.
    Wein LM; D'Amato RM; Perelson AS
    J Theor Biol; 1998 May; 192(1):81-98. PubMed ID: 9628841
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.